These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 8510325

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Plasminogen activators and their potential in therapy.
    Hollander IJ.
    Crit Rev Biotechnol; 1987; 6(3):253-71. PubMed ID: 3146436
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Hybrid molecules: insights into plasminogen activator function.
    Runge MS, Bode C, Haber E, Quertermous T.
    Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766
    [Abstract] [Full Text] [Related]

  • 30. Insight into the profibrinolytic activity of dermatan sulfate: effects on the activation of plasminogen mediated by tissue and urinary plasminogen activators.
    Castañon MM, Gamba C, Kordich LC.
    Thromb Res; 2007 Apr; 120(5):745-52. PubMed ID: 17270255
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
    Veremeenko KN, Kizim AI.
    Vopr Med Khim; 1984 Apr; 30(5):13-22. PubMed ID: 6084892
    [Abstract] [Full Text] [Related]

  • 36. [Staphylokinase--a specific plasminogen activator].
    Rozpończyk E, Szemraj J, Malinowski M, Rozpończyk J.
    Postepy Biochem; 2006 Apr; 52(1):80-6. PubMed ID: 16869305
    [Abstract] [Full Text] [Related]

  • 37. In vitro effects of urokinase--prevention by different inhibitors.
    Oethinger MD, Seifried E.
    Thromb Haemost; 1990 Nov 30; 64(3):402-6. PubMed ID: 1710833
    [Abstract] [Full Text] [Related]

  • 38. Staphylokinase reduces plasmin formation by endogenous plasminogen activators.
    Jin T, Bokarewa M, Zhu Y, Tarkowski A.
    Eur J Haematol; 2008 Jul 30; 81(1):8-17. PubMed ID: 18331597
    [Abstract] [Full Text] [Related]

  • 39. Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator.
    Aisina RB, Moukhametova LI, Varfolomeyev SD.
    Biochemistry (Mosc); 2003 Nov 30; 68(11):1252-60. PubMed ID: 14640969
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.